MX2022004572A - Conjugados farmacologicos de ligandos peptidicos biciclicos. - Google Patents

Conjugados farmacologicos de ligandos peptidicos biciclicos.

Info

Publication number
MX2022004572A
MX2022004572A MX2022004572A MX2022004572A MX2022004572A MX 2022004572 A MX2022004572 A MX 2022004572A MX 2022004572 A MX2022004572 A MX 2022004572A MX 2022004572 A MX2022004572 A MX 2022004572A MX 2022004572 A MX2022004572 A MX 2022004572A
Authority
MX
Mexico
Prior art keywords
drug conjugates
peptide ligand
ligand drug
bicyclic peptide
relates
Prior art date
Application number
MX2022004572A
Other languages
English (en)
Inventor
Gemma Mudd
Paul Beswick
Michael Rigby
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of MX2022004572A publication Critical patent/MX2022004572A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a conjugados farmacológicos que comprenden por lo menos dos polipéptidos, que cada uno está unido de manera covalente a andamios moleculares no aromático, de tal manera que dos o más bucles de péptidos apretados entre puntos de unión al andamio. La invención también se refiere también a composiciones farmacéuticas que comprenden dichos conjugados farmacológicos y al uso de dichos conjugados farmacológicos para evitar, suprimir o tratar enfermedades, tales como las que pueden ser mitigadas mediante muerte celular, en particular enfermedades caracterizadas por tipos de células defectivas, trastornos proliferativos tales como cáncer y trastornos autoinmunes tales como artritis reumatoide.
MX2022004572A 2019-10-15 2020-10-15 Conjugados farmacologicos de ligandos peptidicos biciclicos. MX2022004572A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201914872A GB201914872D0 (en) 2019-10-15 2019-10-15 Bicyclic peptide ligand drug conjugates
PCT/GB2020/052590 WO2021074622A1 (en) 2019-10-15 2020-10-15 Bicyclic peptide ligand drug conjugates

Publications (1)

Publication Number Publication Date
MX2022004572A true MX2022004572A (es) 2022-05-06

Family

ID=68619460

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004572A MX2022004572A (es) 2019-10-15 2020-10-15 Conjugados farmacologicos de ligandos peptidicos biciclicos.

Country Status (12)

Country Link
US (1) US20240173422A1 (es)
EP (1) EP4045089A1 (es)
JP (1) JP2022552839A (es)
KR (1) KR20220088416A (es)
CN (1) CN114901317A (es)
AU (1) AU2020367325A1 (es)
BR (1) BR112022007099A2 (es)
CA (1) CA3154672A1 (es)
GB (1) GB201914872D0 (es)
IL (1) IL292113A (es)
MX (1) MX2022004572A (es)
WO (1) WO2021074622A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020529427A (ja) 2017-08-04 2020-10-08 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB202016331D0 (en) * 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
WO2022253051A1 (zh) * 2021-06-01 2022-12-08 南京明德新药研发有限公司 多肽偶联药物及其应用
GB202114279D0 (en) * 2021-10-06 2021-11-17 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
WO2023066314A1 (zh) * 2021-10-19 2023-04-27 海思科医药集团股份有限公司 Nectin-4的双环肽配体及其用途
CN116768978A (zh) * 2022-03-11 2023-09-19 上海智肽生物科技有限公司 Nectin-4靶向肽化合物及其药物偶联物
CN117003830A (zh) * 2023-08-04 2023-11-07 湖南中晟全肽生化有限公司 靶向Nectin-4的多肽及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
PT1844337E (pt) 2005-01-24 2014-04-03 Pepscan Systems Bv Compostos ligantes, compostos imunogénicos e peptidomiméticos
EP2257624B9 (en) 2008-02-05 2012-08-01 Medical Research Council Methods and compositions
PT3215518T (pt) 2014-10-29 2021-05-25 Bicyclerd Ltd Ligantes de péptido bicíclicos específicos para mt1-mmp
BR112020014576A2 (pt) * 2018-02-23 2020-12-08 Bicycletx Limited Ligantes peptídicos bicíclicos multiméricos
JP7551500B2 (ja) * 2018-04-04 2024-09-17 バイスクルテクス・リミテッド ヘテロタンデム二環式ペプチド複合体
US11180531B2 (en) * 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4

Also Published As

Publication number Publication date
JP2022552839A (ja) 2022-12-20
AU2020367325A1 (en) 2022-05-26
IL292113A (en) 2022-06-01
CN114901317A (zh) 2022-08-12
WO2021074622A1 (en) 2021-04-22
EP4045089A1 (en) 2022-08-24
BR112022007099A2 (pt) 2022-07-05
KR20220088416A (ko) 2022-06-27
GB201914872D0 (en) 2019-11-27
US20240173422A1 (en) 2024-05-30
CA3154672A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
MX2022004572A (es) Conjugados farmacologicos de ligandos peptidicos biciclicos.
PH12020552179A1 (en) Bicyclic peptide ligands specific for nectin-4
PH12020550929A1 (en) Bicyclic peptide ligands specific for epha2
MX2020008791A (es) Ligandos de peptidos biciclicos multimericos.
MX2021013669A (es) Ligandos peptidicos biciclicos especificos para ox40.
MX2021006991A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
MX2020010444A (es) Complejos de péptidos bicíclicos en heterotándem.
EP4219563A3 (en) Methods of treating cancer with anti-pd-1 antibodies
MX2024007140A (es) Conjugados de farmaco-proteina con ciclodextrina.
EP3882270A3 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
SG160224A1 (en) Novel peptides that bind to the erythropoietin receptor
WO2006062685A3 (en) Novel peptides that bind to the erythropoietin receptor
AR102595A1 (es) Anticuerpos anti-ang2 y métodos de utilización
MX2022004989A (es) Composiciones farmaceuticas de albumina y rapamicina.
MX2021006989A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
NZ741780A (en) Anti-htra1 antibodies and methods of use thereof
MA39342B2 (fr) Anticorps il -21
MX2020012273A (es) Proteína de union a nkg2d, cd16 y proteína de activación de fibroblastos.
MX2023012048A (es) Composiciones y metodos para inhibir cetohexoquinasa (khk).
SA523440745B1 (ar) (TfR1) ربائط الببتيد ثنائية الحلقة الخاصة بمستقبلات الترانسفيرين 1
MX2017016195A (es) Variantes de il-37.
MX2024005855A (es) Procedimientos para tratar el cancer.
MX2023005693A (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa.
CY1123041T1 (el) Συνδυασμος κανρενοατης και εξενατιδης
WO2006060148A3 (en) Novel peptides that bind to the erythropoietin receptor